DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma, Non-Hodgkin
MALT Lymphoma

Interventions: Drug: Fludarabine
Drug: Rituximab

First Posted Date: 2005-07-04

Last Posted Date: 2016-08-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 26

Registration Number: NCT00117156

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
University of Rochester Cancer Center, Rochester, New York, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer
Neoplasm Metastasis

First Posted Date: 2005-06-30

Last Posted Date: 2007-12-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 35

Registration Number: NCT00116506

Locations: 🇺🇸
Massachusett General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Radiation: External Beam Radiotherapy
Drug: Flutamide (Eulexin) and Lupron or Zoladex

First Posted Date: 2005-06-28

Last Posted Date: 2022-01-06

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 206

Registration Number: NCT00116220

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: Androgen Hormonal Suppression and Radiation
Drug: Docetaxel
Drug: Androgen Suppression Therapy and Radiation Therapy

First Posted Date: 2005-06-28

Last Posted Date: 2022-01-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 350

Registration Number: NCT00116142

Locations: 🇺🇸
Dana-Farber Cancer Institute and (Sanofi-Aventis Consortium), Boston, Massachusetts, United States

Prostate Immobilization Device Used During Radiation Treatments to Decrease Rectal Bleeding

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2005-06-21

Last Posted Date: 2023-05-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 100

Registration Number: NCT00114985

Title XELOX FOR SALIVARY GLAND CANCERS

Phase 2

Terminated

Conditions: Head and Neck Cancer

Interventions: Drug: Capecitabine
Drug: Oxaliplatin

First Posted Date: 2005-01-10

Last Posted Date: 2017-02-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 9

Registration Number: NCT00101075

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma

Phase 2

Completed

Conditions: Central Nervous System Tumor, Pediatric
Neuroblastoma

Interventions: Drug: temozolomide
Drug: thalidomide

First Posted Date: 2004-12-09

Last Posted Date: 2014-10-07

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 15

Registration Number: NCT00098865

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Talotrexin in Treating Patients With Advanced or Recurrent Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: talotrexin ammonium

First Posted Date: 2004-12-08

Last Posted Date: 2017-12-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 53

Registration Number: NCT00098514

Locations: 🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States

Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)

Phase 3

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: carboplatin
Drug: cisplatin
Drug: docetaxel
Drug: fluorouracil

First Posted Date: 2004-11-09

Last Posted Date: 2013-11-19

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 145

Registration Number: NCT00095875

Locations: 🇺🇸
Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States
🇺🇸
Albert Einstein Cancer Center at Albert Einstein College of Medicine, Bronx, New York, United States
🇺🇸
Eugene M. and Christine E. Lynn Cancer Institute at Boca Raton Community Hospital - Main Campus, Boca Raton, Florida, United States

and more 12 locations

Randomized Amifostine For SCCHN

Phase 2

Completed

Conditions: Head and Neck Cancer
Mucositis
Chemotherapeutic Agent Toxicity
Radiation Toxicity
Xerostomia

Interventions: Drug: Amifostine
Drug: Carboplatin
Radiation: radiation
Drug: Paclitaxel

First Posted Date: 2004-11-09

Last Posted Date: 2017-01-04

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 58

Registration Number: NCT00095927

Locations: 🇺🇸
Goodall Hospital, Sanford, Maine, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 6 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy